52771-99-0

Usage

Uses

Used in Organic Synthesis:
5-Nitro-1,3-dihydroisobenzofuran is utilized as a versatile intermediate in the synthesis of a variety of organic compounds. Its presence of a nitro group allows for the creation of a range of derivatives, which are essential in the development of new pharmaceuticals and agrochemicals.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 5-Nitro-1,3-dihydroisobenzofuran is employed as a key component in the research and development of new drugs. Its unique structure and properties make it a promising candidate for the discovery of novel therapeutic agents.
Used in Antimicrobial Applications:
5-Nitro-1,3-dihydroisobenzofuran has been studied for its potential antimicrobial properties, indicating its use as an antimicrobial agent. This could be particularly beneficial in the development of new treatments for bacterial infections.
Used in Anticancer Research:
5-Nitro-1,3-dihydroisobenzofuran has also been investigated for its potential anticancer properties, making it an important target for research in oncology. Its use in this field could lead to the development of new cancer therapies.
Used in the Agrochemical Industry:
5-Nitro-1,3-dihydroisobenzofuran is also used as a precursor in the synthesis of agrochemicals, contributing to the development of new pesticides and other agricultural chemicals to improve crop protection and yield.

InChI:InChI=1/C8H7NO3/c10-9(11)8-2-1-6-4-12-5-7(6)3-8/h1-3H,4-5H2

Upstream product

• 1013915-62-2 sodium 2-chloro-5-nitrobenzyloxymethyl trifluoroborate 
• 496-14-0 1,3-dihydroisobenzofuran 

Downstream Products

• 61964-08-7 1,3-dihydro-isobenzofuran-5-ylamine 

Relevant academic research and scientific papers

6-MEMBERED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

A compound represented by Formula (I): wherein or the like Y1 is O or the like; Z1 is C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently a hydrogen atom or the like; R1 is substituted or unsubstituted aromatic carbocyclyl or the like; R2a, R2b, R2c and R2d are each independently a hydrogen atom or the like; X is N(R7a) or the like; R7a is a hydrogen atom or the like; R3 is or the like Ring B is a 6-membered aromatic carbocycle or the like; R9a and R10a are each independently halogen or the like; n is an integer from 1 to 5; m is an integer from 0 to 4; and p1 is an integer from 0 to 3, or a pharmaceutically acceptable salt thereof.

FLUOROBORON COMPOUND HAVING AROMATIC RING OR SALT THEREOF, AND PROCESS FOR PRODUCTION OF COMPOUND HAVING CYCLIC ETHER-FUSED AROMATIC RING BY USING THE SAME

Provided is a fluoroboron compound which is highly safe and stable and is capable of forming a cyclic ether-fused ring by the intramolecular alkoxymethylation reaction, or a salt thereof. The compound can be synthesized by the intramolecular alkoxymethylation reaction of a fluoroboron compound represented by the formula (I) or a salt thereof in the presence of a metal catalyst. (wherein the moiety represented by the formula represents an aromatic ring; L represents a substituent such as a halogen atom; R represents a substituted or unsubstituted alkylene group having 1 or 2 carbon atoms; and M represents an alkali metal cation or the like, with the proviso that L and -R-OCH2BF3M are respectively located on contiguous carbon atoms on the aromatic ring, or in the case of a fused aromatic ring, on two carbon atoms adjacent to one carbon at the fused position).

Imidazo pyridine-2-ones and pharmaceutical compositions and methods of treatment utilizing same

1,3-Dihydroimidazo[4,5-b]pyridin-2-ones and corresponding thiones have utility as analgesic, antipyretic and antiinflammatory agents. They are generally prepared by treatment of a 2,3-diaminopyridine with phosgene or thiosphosgene followed by further substitution if desired.

Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-6]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines

In a study of nonsteroidal antiinflammatory and analgesic agents, a series of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)triazolo[4,5-b]pyridines was prepared. Many of the imidazolones were alkylated on the free nitrogen. In a modified Randall-Selitto analgesic assay, the pain thresholds of both the inflamed and normal foot were elevated. This is not commonly observed with nonsteroidal antiinflammatory agents. The most active compounds were 1,3-dihydro-3-[3,4-(methylenedioxy)phenyl]imidazo[4,5-b]pyridin-2-one (I-15) and its N-allyl (I-21) and N-isopropyl (I-121) derivatives. In the triazole series the 3-(2-fluoro- and 2,4-difluorophenyl)triazolo[4,5-b]pyridines (T-1 and T-8) were the best. The imidazole compounds were somewhat superior in analgesic activity to codeine and d-propoxyphene without showing any narcotic characteristics. Some of the compounds also possessed activity against carrageenan-induced foot edema in the rat, so these compounds represent a new class of nonnarcotic analgesic antiinflammatories, capable of producing a greater degree of analgesia than that obtainable with other nonsteroidal antiinflammatory agents.